What changed 10-K

Item 5. Market for Registrant’s Common Equity

2021-03-11 compared with 2020-03-30 · 2 added, 2 removed, 17 unchanged (19% of the section changed)

11 unchanged sentences

We received net proceeds from the IPO of approximately $77.5 million, after deducting underwriting discounts and commissions and offering costs of approximately $12.2 million.

Through December 31, 2019, we used:

Through December 31, 2020, we used the net proceeds as follows:

approximately $8.6 million to fund activities related to commercialization of our gammaCore products which included hiring additional territory business managers as well as patient and professional promotional activities across multiple media channels,

approximately $3.9 million to fund expansion of our clinical program into additional indications in headache and rheumatology,

approximately $5.4 million to fund expansion of our clinical program into additional indications in headache,

approximately $4.4 million for the build out of our specialty distribution channel for the launch of gammaCore Sapphire, and

3 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.